Workflow
Autologous Hematopoietic Stem Cell Transplantation (AHSCT)
icon
Search documents
Adia Nutrition Inc. Appoints Dr. Evan Thomas, MD, PhD, to Drive Adia Med's Specialized Treatment Revolution
Newsfile· 2025-10-21 13:00
Core Insights - Adia Nutrition Inc. has appointed Dr. Evan Thomas as Independent Medical Director for its medical division, Adia Med, to enhance specialized treatment offerings [2][5] - Dr. Thomas will oversee the Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program and finalize protocols for patient intake [2][5] - The company aims to expand access to advanced stem cell solutions through strategic partnerships and licensing opportunities for clinic owners [6][8] Company Overview - Adia Nutrition Inc. is based in Winter Park, Florida, and is publicly traded, focusing on healthcare innovation [7] - The company specializes in stem cell and regenerative products, including AdiaVita and AdiaLink, and is expanding its lab division to include insurance-billable wound care products [7][8] - Adia Med clinics provide specialized regenerative treatments such as stem cell therapies, platelet-rich plasma (PRP), and therapeutic plasma exchange (TPE) [7][8] Leadership and Expertise - Dr. Evan Thomas is recognized for his expertise in oncology and has a significant background in central nervous system (CNS) and functional radiosurgery [4][5] - His leadership is expected to redefine Adia Med's impact on patient care and clinical operations [5] Revenue Generation - Adia Nutrition Inc. generates revenue through service fees, product sales, equity stakes, and insurance billing for healthcare treatments [8]
Adia Nutrition Inc. Supports Heroes and Their Families with TRICARE In-Network Application, Advancing Regenerative Care Through Adia Med
Newsfile· 2025-07-23 13:45
Core Insights - Adia Nutrition Inc. is advancing its regenerative care offerings by filing to become an in-network provider with TRICARE, which serves approximately 9.5 million beneficiaries, including active-duty service members and their families [2][5] - The company anticipates approval as a United Healthcare provider by August 1, 2025, which will further enhance its healthcare access initiatives [2][5] - Adia Med aims to secure TRICARE in-network provider status by August 31, 2025, tapping into a program that disbursed $50.6 billion for medical treatments in FY2019 [2][3] Company Developments - Adia Med plans to offer innovative regenerative treatments such as Umbilical Cord Blood Stem Cell therapies, Autologous Hematopoietic Stem Cell Transplantation, and Therapeutic Plasma Exchange, targeting conditions like Multiple Sclerosis and joint pain [3][5] - The filing with TRICARE complements Adia Med's progress with United Healthcare, where the company has begun submitting patient insurance claims, indicating near-final integration into the healthcare system [5] - By securing in-network status with both TRICARE and United Healthcare, Adia Med will join a select group of providers recognized for clinical excellence and compliance, enhancing patient care and insurance reimbursement opportunities [5][6] Market Positioning - The strategic move to join TRICARE's network is expected to make advanced regenerative therapies more accessible and affordable for military personnel and their families, aligning with the company's mission to revolutionize healthcare accessibility [3][5] - Adia Nutrition Inc. operates with a dual focus on premium organic supplements and leading-edge stem cell therapies, positioning itself as a key player in the healthcare and wellness industry [6]